<html xmlns="http://www.w3.org/1999/xhtml" xmlns="http://www.w3.org/1999/xhtml">
 <head xmlns="http://www.w3.org/1999/xhtml">
 <title xmlns="http://www.w3.org/1999/xhtml"></title>
 </head>
 <body xmlns="http://www.w3.org/1999/xhtml">
 
 Illumina, Inc. ILMN announced today that Mark Van Oene has 
 been named Chief Commercial Officer. Van Oene was previously Illumina's 
 Senior Vice President of the Americas region and subsequently named 
 interim Chief Commercial Officer in late 2016.
 

This Smart News Release features multimedia. View the full release here: 
<a xmlns="http://www.w3.org/1999/xhtml" href="http://www.businesswire.com/news/home/20170522005470/en/" rel="nofollow" rel="nofollow">http://www.businesswire.com/news/home/20170522005470/en/
</a>
<div xmlns="http://www.w3.org/1999/xhtml" id="bwbodyimg" style="width:370px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"> 
 <img xmlns="http://www.w3.org/1999/xhtml" alt="Illumina Chief Commercial Officer Mark Van Oene (Photo: Business Wire)" src="http://mms.businesswire.com/media/20170522005470/en/588135/4/Mark_Van_Oene_6_Public.jpg"></img>
 Illumina Chief Commercial Officer Mark Van Oene (Photo: Business Wire) 
</div>

 
 "Mark is a great leader for our commercial organization, possessing deep 
 genomics expertise and over a decade of experience building and running 
 strong sales and marketing teams," said Francis deSouza, Illumina 
 President and Chief Executive Officer. "As interim Chief Commercial 
 Officer Mark has guided Illumina through two strong quarters, including 
 the launch of NovaSeq, and laid the foundation for our future growth. I 
 am excited to continue to work closely with Mark to expand our 
 commercial capability as we grow in research and clinical markets around 
 the world."
 
 
 Van Oene joined Illumina in 2006 as Regional Account Manager for Canada. 
 In 2008, Van Oene was promoted to Senior Director of Sales for the 
 Americas. Four years later, he was promoted to Vice President with 
 responsibility for global sales. From 2012 through 2014, Van Oene led 
 the team to grow revenues from $1.06B to $1.42B. In early 2014, Van Oene 
 was named the General Manager for the Americas region, advancing to 
 Senior Vice President in April 2016. During that time, the Americas 
 compound annual growth rate exceeded 20%.
 
 
 As Chief Commercial Officer, Van Oene will be responsible for world-wide 
 sales, services and marketing at Illumina. He will report to President 
 and CEO, Francis deSouza.
 
 
 Van Oene earned a Bachelor of Science degree in Biochemistry from 
 Western University in London, Ontario, Canada.
 
 
 About Illumina
 
 
 Illumina is improving human health by unlocking the power of the genome. 
 Our focus on innovation has established us as the global leader in DNA 
 sequencing and array-based technologies, serving customers in the 
 research, clinical and applied markets. Our products are used for 
 applications in the life sciences, oncology, reproductive health, 
 agriculture, and other emerging segments. To learn more, visit <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.illumina.com%2F&amp;esheet=51562863&amp;newsitemid=20170522005470&amp;lan=en-US&amp;anchor=www.illumina.com&amp;index=1&amp;md5=072c8c30e75cfb072dda545d171342b8" rel="nofollow" rel="nofollow">www.illumina.com</a> and 
 follow @illumina.
 
 <img xmlns="http://www.w3.org/1999/xhtml" alt="" src="http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20170522005470r1&amp;sid=benz2&amp;distro=nx&amp;lang=en"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.businesswire.com/news/home/20170522005470/en/" rel="nofollow" rel="nofollow">http://www.businesswire.com/news/home/20170522005470/en/</a></body></html>

Press Releases

Illumina Names Mark Van Oene Chief Commercial Officer, Sales Leader Brings Genomics Expertise and Strong Commercial Leadership Experience to the Role - Illumina (NASDAQ:ILMN)

Illumina

ILMN

Illumina Names Mark Van Oene Chief Commercial Officer, Sales Leader Brings Genomics Expertise and Strong Commercial Leadership Experience to the Role


Segal Marco Advisors, one of the largest U.S.-based investment consultancies, has received a 2024 Greenwich Quality Leader award for Overall U.S. Investment Consulting in the Large Consultants category by Coalition

Segal Marco Advisors Receives the Greenwich Quality Leader Designation for the Sixth Time


WestRock Company (NYSE:WRK) today reported that its board of directors declared a quarterly dividend of $0.3025 per share on its common stock. The quarterly dividend of $0.3025 per share will be paid to stockholders of

WestRock Announces Quarterly Dividend of $0.3025 Per Share


Collaboration Highlights C2N&#39;s Growing Global Footprint for Offering Blood Biomarker Research Testing That&#39;s Transforming Clinical Research and Early Diagnosis


C₂N Diagnostics, LLC (&#34;C2N&#34;), a specialty diagnostics

C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer&#39;s Disease and Brain Research Market


The law firm of Federman &amp; Sherwood has initiated an investigation into Transamerica Life Insurance Company with respect to their recent data breach. A recent report from the Attorney General of South Carolina

Federman &amp; Sherwood Investigates Transamerica Life Insurance Company for Data Breach


The Food is Medicine Institute at the Tufts University Friedman School of Nutrition Science and Policy convened the second annual Food is Medicine Summit this week. The Summit provided an opportunity for leaders to

Nourishing Tomorrow: How &#39;Food is Medicine&#39; Advances Food Retailing and Positive Outcomes for Nutrition Responsive Health Conditions


Learn4Life&#39;s child development program offers a plethora of opportunities


Dual enrollment courses help high schoolers at Learn4Life earn college credits and prepare for rewarding careers


Summer H. is fascinated by